Utility of FDG PET‐CT in CT Stage IA non‐small cell lung cancer: The New Zealand Te Whatu Ora Northern region experience

Author:

Kelly Richard J1ORCID,Anderson Graeme D1,Joshi Budresh S1,Donald Jennifer J1

Affiliation:

1. Department of Radiology Counties Manukau Health Auckland New Zealand

Abstract

AbstractIntroductionOur objective was to investigate the utility of fluorodeoxyglucose positron emission tomography‐computed tomography (FDG PET‐CT) in assessing CT Stage 1A non‐small cell lung cancer (NSCLC) in patients under consideration for curative treatment. Performing FDG PET‐CT in these patients may lead to unnecessary delays in treatment if it can be shown to provide no added value.MethodsWe retrospectively reviewed 735 lesions in 653 patients from the New Zealand Te Whatu Ora Northern region lung cancer database with suspected or pathologically proven Stage 1A NSCLC on CT scan who also underwent FDG PET‐CT imaging. We determined how often FDG PET‐CT findings upstaged patients and then compared to pathological staging where available.ResultsFDG PET‐CT provided an overall upstaging rate of 9.7%. Category‐specific rates were 0% in Tis, 0.9% in T1mi, 7.4% in T1a, 10% in T1b and 12% in T1c groups. The percentage of lesions upstaged on FDG PET‐CT that remained Stage 1A was 100% in T1mi, 100% in T1a, 47.1% in T1b and 40.7% in T1c groups. The P value was statistically significant at 0.004, indicating upstaging beyond Stage 1A was dependent on T category.ConclusionOur data suggests that FDG PET‐CT is indicated for T1b and T1c lesions but is of limited utility in Tis, T1mi and T1a lesions. Adopting a more targeted approach and omitting FDG PET‐CT in patients with Tis, T1mi, and T1a lesions may benefit all patients with lung cancer by improving accessibility and treatment timelines.

Publisher

Wiley

Reference22 articles.

1. New Cancer Registrations and Deaths – Series – Health New Zealand|Te Whatu Ora. Available from URL:www.tewhatuora.govt.nz.https://www.tewhatuora.govt.nz/our-health-system/data-and-statistics/nz-health-statistics/health-statistics-and-data-sets/cancer-data-and-statistics/new-cancer-registrations-and-deaths-series/

2. Disparities in Cancer-Specific Survival Between Māori and Non-Māori New Zealanders, 2007-2016

3. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

4. ACR Appropriateness Criteria Non-invasive Clinical Staging of Bronchogenic Carcinoma

5. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3